Biggest healthcare deals of 2018

Amy Baxter | | Health Exec | Policy & Regulations

The global healthcare industry continued its hot streak in 2018, with bigger transactions that could reshape the landscape.

In a period of rapid consolidation across the industry, transaction volume is expected to remain high next year, as well. While volume soared in 2018, a number of large transaction marked the year.

Here are the biggest international healthcare deals of 2018, as ranked by Business Insider:

  1. Takeda’s (Japan) $77 billion acquisition of Shire (United States)
  2. Cigna’s $67 billion takeover of Express Scripts (United States)
  3. GlaxoSmithKline’s (UK) $13 billion stake in Novartis (Switzerland)
  4. Sanofi’s (France) $11 billion purchase of Bioverativ (United States)
  5. KKR’s $10 billion acquisition of Envision (United States)
  6. Celgene’s $9 billion acquisition of Juno (United States)
  7. Novartis’ (Switzerland) $8 billion purchase of AveXis (Unites States)

See the full story below:

Healthcare deals hit an all-time record in 2018. See the 7 biggest tie-ups that…

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders
Advancing AI for vascular surgery will require a commitment to data integrity

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.